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1815Letters to the EditorQuantiﬁcation of
Atherosclerotic Coronary Plaque
The Missing Link Between Elevated
Biochemical Markers and Adverse
Outcomes in the “Vulnerable” Patient?We would like to congratulate Versteylen et al. (1) on their recent
paper. In a relatively large cohort of 1,650 patients who underwent
cardiac computed tomographic angiography (CCTA) for stable
chest pain syndrome, the authors demonstrated that semi-
automated coronary plaque quantiﬁcation provided incremental
value for the identiﬁcation of patients at high risk for future acute
coronary syndromes (ACS), surpassing that provided both by
clinical risk proﬁling and by visual analysis of CCTA datasets
(including calcium scoring, lumen narrowing, and number of
coronary segments with noncalciﬁed plaque). The authors suggest
that such semiautomated plaque quantiﬁcation can be implemented
in the clinical routine, aiding the individualized prediction of ACS in
patients with stable coronary artery disease (CAD).
In the past, several studies demonstrated visually-assessed
CCTA parameters, including the extent of CAD, noncalciﬁed
plaque, and the number of coronary segments containing plaque, as
robust independent predictors of cardiovascular events in patients
with stable CAD (reviewed in Bamberg et al. [2]). On the other
hand, in the recently published PEACE (Prevention of Events
With Angiotensin-Converting Enzyme Inhibitor Therapy) study,
cardiac troponins were independent markers of cardiac outcomes in
a large patient cohort (n ¼ 3,623) with stable CAD and preserved
left ventricular function (3). We previously demonstrated that high-
sensitivity cardiac troponin T (hsTnT) is associated with quanti-
tative characteristics of coronary plaque composition by CCTA in
patients with stable CAD (4,5), suggesting that such increased
hsTnT levels may be the consequence of repetitive clinically silent
plaque ruptures in patients with a high extent of diffuse athero-
sclerotic disease. Although such phenomena may be present in
presumably stable patients, preceding the clinical manifestation of
infarction or sudden cardiac death, the underlying pathophysiologic
mechanisms are not yet fully understood. Therefore, hsTnT-
orientated therapeutic strategies have not been implemented in
the clinical realm so far. In the present study, Versteylen et al. (1),
for the ﬁrst time to our knowledge in the current literature,
provided the link between quantitative plaque composition assess-
ment and clinical outcomes. Their study underscores the impor-
tance of objective and quantitative coronary plaque composition
assessment, which may possibly represent the key for understanding
the high risk for future cardiovascular events in the “vulnerable”
patient with stable symptoms but high risk for future ACS.
Despite the comprehensive methodological approach, however,
the present study has been conducted retrospectively and therefore
has some limitations. First of all, it is not clear why only
101 randomly selected “controls” and not all 1,625 patientswithout ACS at follow-up were analyzed. The authors selected
their controls out of 993 patients with CAD and without ACS,
which may represent a serious selection bias because even patients
with angiographically normal coronaries may present with ACS
due to embolism of coronary atherothrombotic debris. Further-
more, the relatively high observer variability with quantiﬁcation of
noncalciﬁed plaque is not consistent with previous reports (6). In
addition, the time spent for such semiautomated measures was not
mentioned by the authors. Despite these limitations, the study by
Versteylen et al. (1) represents an important cornerstone toward
the personalized risk assessment for future cardiac events in
presumably stable CAD patients. This new type of quantitative
analysis improved the prediction of cardiac outcomes, surpassing
that provided by clinical risk proﬁling and by conventional CCTA
readings (area under the curve rose from 0.64 to 0.79 with
application of quantitative measures). Further studies are now
warranted where the value of 1) clinical risk factors; 2) conven-
tional CCTA ﬁndings; 3) quantitative measures of atherosclerotic
plaque composition by CCTA; and 4) cardiac biomarkers, such
as hsTnT, will be prospectively evaluated for the prediction of
cardiac endpoints in patients with stable CAD. Possibly, and in
light of the availability of a number of modern agents (including
different P2Y12 inhibitors of different strengths, PCSK9 inhibitors
with different low-density lipoprotein targets, high-density lipo-
protein modiﬁers, and soluble receptor for advanced glycation
endproducts modulating agents targeting vascular inﬂammation),
cardiac biomarkers such as the hsTnT may present novel thera-
peutic targets in future interventional pharmacotherapy studies.
Thus, patients with increased atherosclerotic burden, identiﬁed
as high-risk candidates for future ACS, may undergo combined
treatment with 1 or several of the above-mentioned agents. In
light of the fact that CCTA acquisitions currently require a radi-
ation exposure comparable to that of calcium scoring (1.0 to
1.5 mSv), longitudinal CCTA studies may be able to non-
invasively monitor mechanisms of plaque regression during
pharmacologic intervention.*Grigorios Korosoglou, MD
Hugo A. Katus, MD
*Department of Cardiology
University of Heidelberg
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Coronary Plaque
The Missing Link Between Elevated
Biochemical Markers and Adverse
Outcomes in the “Vulnerable” Patient?We greatly appreciate the comments made by Drs. Korosoglou and
Katus regarding our paper (1). The authors acknowledge the
promising potential of plaque quantiﬁcation for individualized
prediction of acute coronary syndrome (ACS). At the same time,
highly-sensitive cardiac troponin T (hsTnT) also has important
prognostic implications, although indeed the pathophysiologic
mechanism is not fully understood. Previous results showed hsTnT
levels to be associated with extent of coronary artery disease (2) and
to have independent prognostic value on top of stenosis severity, as
assessed by cardiac computed tomographic angiography (3). The
suggestion that hsTnT elevation might be a marker of plaque
instability is very interesting and could possibly explain these
ﬁndings. We agree that the association between high-risk plaque
features and hsTnT levels points toward this direction (4). Our
current investigation is really a ﬁrst step to identify the additional
value of coronary plaque quantiﬁcation, and it would be a very
interesting next study to validate serum biomarkers again using
high-risk imaging parameters.
The authors express some methodological concerns. Regarding
selection bias, our objective was to investigate the potential addi-
tional value of plaque quantiﬁcation over conventional cardiac
computed tomographic angiography readings. In fact, we compared
2 methods within the same patient group. That is the reason whywe chose a randomly-selected control population: the inﬂuence of
selection bias would be irrelevant to this comparison. As mentioned
by the authors, the fact that ACS can also occur in the absence of
angiographically-visible coronary artery disease is really an intrinsic
limitation of plaque assessment in general (and could limit its
prognostic value in a prospective study). Unfortunately, predicting
these elusive ACS cases remains challenging. The semiautomated
nature of our quantiﬁcation algorithm results in approximately
15 min operating time per patient and, indeed, some interobserver
variability. For clinical practice, the development of a reliable
automated method would be beneﬁcial.
Most important, a prospective study on plaque quantiﬁcation
could validate our suggested high-risk parameters. This informa-
tion could help us to identify a simple and clinically useful “risk
score” based on imaging data. Combining coronary imaging and
serum biomarkers (such as hsTnT) may possibly further improve
individualized risk assessment. We fully agree with the authors
that, regarding the wide array of novel therapeutic options, this
would be a very important goal to pursue.*Mathijs O. Versteylen, MD
Ivo A. Joosen, MD
Leonard Hofstra, MD, PhD
*Department of Cardiology
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